Pharmacy Insights Podcast

Optum Rx

5.0 (11)
BUSINESS

Introducing the Pharmacy Insights Podcast from Optum Rx. This ongoing series features our most experienced leaders examining the topics currently challenging pharmacy benefit plan sponsors. Join Optum Rx Senior Vice President of Clinical Consulting Scott Draeger as he interviews leading experts to uncover the emerging solutions needed to control rising prescription drug costs and ensure the best possible quality of care.

SEP 13

Biosimilars boom: The next era of adoption

On this episode of the Pharmacy Insights podcast, host Scott Draeger welcomes Optum Rx SVP of Industry Relations, Jamey Millar and Optum Rx SVP of formulary management, Savitha Vivian to discuss the implications of new biosimilar alternatives to expensive biologic drugs.

18 min
APR 30

Connections that count: Redefining the PBM experience

While the operational side of the pharmacy care services business rarely garners headlines, the efforts of operations teams are vital to making prescription medications accessible and affordable. Optum Rx Senior Vice President of Clinical Consulting, Scott Draeger recently welcomed Jason Greenberg, Optum Rx Chief of Operations, and Katie Schumacher, Vice President of digital products at Optum Rx to discuss how ongoing innovations in operations are helping to help improve the pharmacy benefit management experience for plan sponsors, providers, and members.

23 min
FEB 13

The New Drugs Plan Sponsors Need to Watch For

Host Scott Draeger welcomes Optum Rx Vice President of Trend Insights & Analytics Michelle Kamprath and Optum Rx Senior Director of Drug Pipeline & Surveillance Bill Dreitlein for a lively discussion of the year ahead in pharmacy. Find out which trends are expected to make noise in 2024 including the ongoing obesity drug dilemma facing plan sponsors, the impact of the profusion of biosimilars on drug costs, and some noteworthy drug candidates currently advancing through the pipeline.

33 min
11/07/2023

Preparing For the Gene Therapy Era

Gene therapies represent a true revolution in the way certain genetic diseases are treated. They are also the most expensive drugs in history. In this episode, Optum Rx Senior Vice President of Clinical Consulting Scott Draeger welcomes Nick Cashman, Specialty Clinical Consultant for Optum Rx, and Arash Sadeghi, Clinical Pharmacist, Pipeline & Drug Surveillance at Optum Rx. They dive in on the science of gene therapies and discuss what measures plan sponsors can take to prepare as these formerly rare medicines begin to be used for more diseases.

23 min
10/04/2023

Making the Invisible Visible: Why Health Equity Matters

Affording everyone a fair and just opportunity to attain their highest level of health is an ongoing challenge. To better understand the issue, Optum Rx Senior Vice President of Clinical Consulting Scott Draeger welcomed Dr. Sumit Dutta, Chief Medical Officer for OptumRx, and Corey Coleman, Vice President of OptumRx Health Equity and Strategic Partnerships for a recent episode of the Pharmacy Insights Podcast. Together they discussed the challenges of achieving Health Equity and the steps the Optum Rx is taking to make an impact.

27 min
05/31/2023

How Choice and Transparency are Changing the PBM Industry

As increasingly expensive medications continue to enter the market and questions about prescription drug affordability become everyday topics of conversation, the pharmacy benefit management space is undergoing profound changes. To get a sense of the forces driving these changes, Optum Rx Senior Vice President of Clinical Consulting, Scott Draeger welcomed Optum Rx president and Chief Operating Officer Jon Mahrt for a recent episode of the Pharmacy Insights Podcast. Together they discuss how issues of access, affordability, and transparency have become the new imperatives for pharmacy benefit management and the innovations addressing these challenges.

18 min
03/29/2023

The Seismic Shift in Weight Loss Medicines

One of the most pronounced changes in the pharmacy landscape over the past year has been the rapid emergence of a new class of medications for weight loss known as GLP-1 agonists. Dr. Ana Bhatnagar, Optum Rx Associate Chief Medical Officer, and Dr. Travis Baughn, Optum Rx Vice President of Clinical Solutions join us to discuss what broader use of these promising but expensive medications for weight loss means for both patients and plan sponsors.

24 min
11/21/2022

The risky business of alternative funding

Guest: Optum Rx Chief Pharmacy Officer, Michael Einodshofer.As costly specialty medications continue to enter the market, “alternative funding” is pitched as a way for self-funded employers to make their employees and dependents eligible for “free” medications. Is this a sustainable solution? And what financial, clinical, and even legal risks does this approach entail?

14 min
10/26/2022

What you can and can’t expect from biosimilars.

Guest: Sr. Vice President, Optum Rx Clinical and Formulary Services, Savitha Vivian. Long established in Europe, biosimilar alternatives to popular and costly biologic drugs are finally poised to make an impact in the U.S. With biosimilar alternatives to Humira now launching, what does that mean for prescription drug spending?

13 min
09/14/2022

What’s happening in Specialty Pharmacy?

Guest: Optum Rx Chief Pharmacy Officer, Michael Einodshofer.Specialty medications continue to be the single largest driver of prescription drug spending. What separates specialty from traditional pharmacy and what specifics steps can be taken to mitigate rising specialty spend? What do new advances such as gene therapies mean for future specialty costs?

16 min

10 Episodes

out of 5

11 Ratings

Creator

Optum Rx
Years Active

2022 - 2024
Episodes

10
Rating

Clean
Show Website

Pharmacy Insights Podcast

Pharmacy Insights Podcast

Episodes

Biosimilars boom: The next era of adoption

Connections that count: Redefining the PBM experience

The New Drugs Plan Sponsors Need to Watch For

Preparing For the Gene Therapy Era

Making the Invisible Visible: Why Health Equity Matters

How Choice and Transparency are Changing the PBM Industry

The Seismic Shift in Weight Loss Medicines

The risky business of alternative funding

What you can and can’t expect from biosimilars.

What’s happening in Specialty Pharmacy?

Ratings & Reviews

About

Information

You Might Also Like